Testing blood test–guided treatment for GI cancers in remission
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent
- You have one of these cancers: colon, stomach, pancreas, liver, or bile duct/gallbladder cancer (adenocarcinoma or related type confirmed by lab testing)
- You finished all curative-intent treatment (surgery and any needed chemo/radiation) and now have no visible cancer on scans and physical exam within the last 28 days
- Your ctDNA blood test (Signatera) was positive within 28 days before joining, and the test was taken within 1 year of finishing treatment
- Your health is good enough for study treatment (performance status 0–2) and your bloodwork/organ tests meet required ranges
- If you can become pregnant or father a child, you must use effective contraception and follow pregnancy/sex and sperm/egg-donation rules during and after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
This trial tests whether using a blood test for cancer DNA (ctDNA) can help decide if more chemotherapy is needed after surgery and chemo for advanced stomach cancer. It may help tailor treatment to your individual risk of cancer returning.
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
This trial tests whether using a blood test for tumor DNA (ctDNA) can help decide who needs more chemotherapy after surgery for advanced stomach cancer. The goal is to personalize treatment and avoid unnecessary side effects.
This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.